Association of a Mediterranean Diet With Outcomes for Patients Treated With Immune Checkpoint Blockade for Advanced Melanoma

被引:33
|
作者
Bolte, Laura A. [1 ,2 ,3 ]
Lee, Karla A. [4 ]
Bjork, Johannes R. [1 ,2 ,3 ]
Leeming, Emily R. [4 ]
Campmans-Kuijpers, Marjo J. E. [1 ,2 ]
de Haan, Jacco J. [1 ,2 ,5 ]
Vila, Arnau Vich [1 ,2 ,3 ]
Maltez-Thomas, Andrew [6 ]
Segata, Nicola [6 ,7 ]
Board, Ruth [8 ]
Harries, Mark [9 ]
Lorigan, Paul [10 ]
de Vries, Elisabeth G. E. [2 ,5 ]
Nathan, Paul [11 ]
Fehrmann, Rudolf [2 ,5 ]
Bataille, Veronique [4 ,12 ]
Spector, Tim D. [4 ]
Hospers, Geke A. P. [2 ,5 ]
Weersma, Rinse K. [1 ,2 ]
机构
[1] Univ Groningen, Dept Gastroenterol & Hepatol, Groningen, Netherlands
[2] Univ Med Ctr Groningen, Groningen, Netherlands
[3] Univ Groningen, Dept Genet, Groningen, Netherlands
[4] Kings Coll London, Dept Twin Res & Genet Epidemiol, London, England
[5] Univ Groningen, Dept Med Oncol, Groningen, Netherlands
[6] Univ Trento, Dept Cellular Computat & Integrat Biol, Trento, Italy
[7] European Inst Oncol, IRCSS, Milan, Italy
[8] Lancashire Natl Hlth Serv NHS Fdn Trust, Royal Preston Hosp, Dept Med Oncol, Fulwood, England
[9] Guys & St Thomass NHS Trust, Guys Canc Ctr, Dept Med Oncol, London, England
[10] Christie NHS Fdn Trust, Dept Dermatol, Manchester, England
[11] Mt Vernon Canc Ctr, Dept Med Oncol, Northwood, England
[12] West Hertfordshire NHS Trust, Dept Dermatol, Watford, England
关键词
IMMUNOTHERAPY; QUALITY; CANCER;
D O I
10.1001/jamaoncol.2022.7753
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
IMPORTANCE Immune checkpoint blockade (ICB) has improved the survival of patients with advanced melanoma. Durable responses are observed for 40% to 60% of patients, depending on treatment regimens. However, there is still large variability in the response to treatment with ICB, and patients experience a range of immune-related adverse events of differing severity. Nutrition, through its association with the immune system and gut microbiome, isa poorly explored but appealing target with potential to improve the efficacy and tolerability of ICB.OBJECTIVE To investigate the association between habitual diet and response to treatment with ICB. DESIGN, SETTING, AND PARTICIPANTS This multicenter cohort study (the PRIMM study) was conducted in cancer centers in the Netherlands and UK and included 91 ICB-naive patients with advanced melanoma who were receiving ICB between 2018 and 2021.EXPOSURES Patients were treated with anti-programmed cell death 1 and anti-cytotoxic T lymphocyte-associated antigen 4 monotherapy or combination therapy. Dietary intake was assessed through food frequency questionnaires before treatment.MAIN OUTCOMES AND MEASURES Clinical end points were defined as overall response rate (ORR), progression-free survival at 12 months (PFS-12), and immune-related adverse events that were grade 2 or higher.RESULTS There were a total of 44 Dutch participants (mean [SD] age, 59.43 [12.74] years; 22 women [50%]) and 47 British participants (mean [SD] age, 66.21 [16.63] years; 15 women [32%]). Dietary and clinical data were prospectively collected from 91 patients receiving ICB between 2018 and 2021 for advanced melanoma in the UK and the Netherlands. Logistic generalized additive models revealed positive linear associations between a Mediterranean dietary pattern that was high in whole grains, fish, nuts, fruit, and vegetables and the probability of ORR and PFS-12 (probability of 0.77 for ORR; P = .02; false discovery rate, 0.032; effective degrees of freedom, 0.83; probability of 0.74 for PFS-12; P = .01; false discovery rate, 0.021; effective degrees of freedom, 1.54).CONCLUSIONS AND RELEVANCE This cohort study found a positive association between a Mediterranean diet, a widely recommended model of healthy eating, and response to treatment with ICB. Large prospective studies from different geographies are needed to confirm the findings and further elucidate the role of diet in the context of ICB.
引用
收藏
页码:705 / 709
页数:5
相关论文
共 50 条
  • [41] Germline variants in exonic regions have limited impact on immune checkpoint blockade clinical outcomes in advanced melanoma
    Montaudie, Henri
    Beranger, Guillaume Emmanuel
    Reinier, Frederic
    Nottet, Nicolas
    Martin, Helene
    Picard-Gauci, Alexandra
    Troin, Laura
    Ballotti, Robert
    Passeron, Thierry
    PIGMENT CELL & MELANOMA RESEARCH, 2021, 34 (05) : 978 - 983
  • [42] Immune checkpoint blockade with concurrent electrochemotherapy in advanced melanoma: a retrospective multicenter analysis
    Markus V. Heppt
    Thomas K. Eigentler
    Katharina C. Kähler
    Rudolf A. Herbst
    Daniela Göppner
    Thilo Gambichler
    Jens Ulrich
    Edgar Dippel
    Carmen Loquai
    Beatrice Schell
    Bastian Schilling
    Susanne G. Schäd
    Erwin S. Schultz
    Fanny Matheis
    Julia K. Tietze
    Carola Berking
    Cancer Immunology, Immunotherapy, 2016, 65 : 951 - 959
  • [43] Immune checkpoint blockade with concurrent electrochemotherapy in advanced melanoma: a retrospective multicenter analysis
    Heppt, Markus V.
    Eigentler, Thomas K.
    Kaehler, Katharina C.
    Herbst, Rudolf A.
    Goeppner, Daniela
    Gambichler, Thilo
    Ulrich, Jens
    Dippel, Edgar
    Loquai, Carmen
    Schell, Beatrice
    Schilling, Bastian
    Schaed, Susanne G.
    Schultz, Erwin S.
    Matheis, Fanny
    Tietze, Julia K.
    Berking, Carola
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2016, 65 (08) : 951 - 959
  • [44] Immune checkpoint blockade with concurrent electrochemotherapy in advanced melanoma: a retrospective multicenter analysis
    Heppt, M.
    Eigentler, T.
    Kahler, K.
    Herbst, R.
    Goppner, D.
    Gambichler, T.
    Ulrich, J.
    Dippel, E.
    Loquai, C.
    Schell, B.
    Schilling, B.
    Schad, S.
    Schultz, E.
    Matheis, F.
    Tietze, J.
    Berking, C.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2016, 14 : 10 - 10
  • [45] A RNA signature predicts outcomes in immune checkpoint blockade treated gastrointestinal cancer patients.
    Lu, Zhihao
    Chen, Huan
    Li, Shuang
    Jiao, Xi
    Wu, Lihong
    Yu, Jianing
    Shen, Lin
    Zhang, Henghui
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [46] Melanoma-Specific Clinical Outcomes of Inpatient Immune Checkpoint Blockade Treatment
    Loo, Kimberly
    Kalvin, Hannah L.
    Panageas, Katherine S.
    Park, Vivian
    Postow, Michael A.
    ONCOLOGIST, 2022, 27 (09): : E755 - E758
  • [47] Association of race with clinical outcomes in patients with advanced renal cell carcinoma (aRCC) treated with immune checkpoint inhibitors (ICIs)
    Choi, Yujin
    Yildirim, Ahmet
    Wei, Mengting
    Liu, Yuan
    Goswamy, Rohit Vivek
    Brown, Jacqueline T.
    Nazha, Bassel
    Martini, Dylan J.
    Hartman, Caitlin
    McClintock, Greta Russler
    Zhuang, Tony
    Kissick, Haydn
    Harris, Wayne B.
    Carthon, Bradley Curtis
    Kucuk, Omer
    Master, Viraj A.
    Bilen, Mehmet Asim
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [48] Association of baseline inflammatory biomarkers and clinical outcomes in patients with advanced renal cell carcinoma treated with immune checkpoint inhibitors
    Yildirim, Ahmet
    Wei, Mengting
    Liu, Yuan
    Nazha, Bassel
    Brown, Jacqueline T.
    Carthon, Bradley C.
    Choi, Yujin
    Suh, Lauren
    Goswamy, Rohit V.
    Mcclintock, Greta R.
    Hartman, Caitlin
    Caulfield, Sarah
    Ciuro, Jordan
    Goldman, Jamie M.
    Harris, Wayne B.
    Kucuk, Omer
    Master, Viraj A.
    Bilen, Mehmet A.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2025, 17
  • [49] Outcome and impact of immune related adverse events in patients with advanced melanoma treated with checkpoint inhibitors
    Angeles, A.
    Wind, K.
    Tong, C.
    Lee, D. G.
    Bernstein, V.
    Metcalf, C.
    Bahl, G.
    Nguyen, T. P.
    Savage, K. J.
    ANNALS OF ONCOLOGY, 2021, 32 : S878 - S878
  • [50] Development and Validation of a Prognostic Risk Model for Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors
    Stukalin, Igor
    Navani, Vishal
    Gupta, Mehul
    Ruan, Yibing
    Boyne, Devon J.
    O'Sullivan, Dylan E.
    Meyers, Daniel E.
    Goutam, Siddhartha
    Sander, Michael
    Ewanchuk, Benjamin W.
    Brenner, Darren R.
    Suo, Aleksi
    Cheung, Winson Y.
    Heng, Daniel Y. C.
    Monzon, Jose G.
    Cheng, Tina
    ONCOLOGIST, 2023, 28 (09): : 812 - 822